 Home > Active Ingredient News > Study of Nervous System > Lancet: Levetiracetam vs. Valproate as the first-line treatment for idiopathic generalized or intractable epilepsy

Lancet: Levetiracetam vs. Valproate as the first-line treatment for idiopathic generalized or intractable epilepsy

 Last Update: 2021-04-17
 Source: Internet
 Author: User

Tags

drug test pills

ciprofloxacin treatment

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

medsci.

Sodium valproate is currently the first-line treatment for newly diagnosed idiopathic comprehensive or difficult-to-classify epilepsy patients.

Diagnostic Recently researchers compared levetiracetam and valproate for newly diagnosed idiopathic generalized or long-term clinical efficacy and cost-effectiveness is difficult to classify patients with epilepsy recently researchers compared levetiracetam and valproate Long-term clinical efficacy and cost-effectiveness of sodium phosphate in newly diagnosed patients with idiopathic comprehensive or intractable epilepsy

The SANAD II study was carried out in 69 adult and pediatric neuromedical centers in the United Kingdom.

520 patients participated in the study, 260 in each group, and the follow-up period was 2 years.

The intention analysis showed that the levetiracetam group did not reach the non-inferiority endpoint (HR 1.

Studies believe that for newly diagnosed patients with idiopathic generalized or intractable epilepsy, levetiracetam is inferior to sodium valproate in terms of therapeutic effect and cost-effectiveness .

For newly diagnosed patients with idiopathic generalized or intractable epilepsy, levetiracetam is inferior to valproate in terms of therapeutic effect and cost-effectiveness.

Original source:

Anthony Marson et al.

The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial in this message

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Sodium bromide airuike

CAS No.: 7647-15-6

Industrial Grade

$10/KG EXW

Brivaracetam357336-20-0

CAS No.: 357336-20-0

API Grade

$100/KG EXW

Quetiapine fumarate CAS 111974-72-2

CAS No.: 111974-72-2

Pharmaceutical Grade

$100/KG EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.